Federated/May retail giant
This article was originally published in The Rose Sheet
Executive Summary
Federated Department Stores agrees to buy The May Department Stores Company for $11 bil. in stock, creating a $30 bil. national department store giant that will change the face of prestige retailing. Firms announced the deal, which includes assumption of May's $6 mil. debt, Feb. 28. Closing is anticipated in Q3, after which Federated will operate 950 department stores and 700 bridal and formalwear stores, including May chains like Lord & Taylor, Filene's, Marshall Field's and Hecht's in addition to its own Macy's, Bloomingdale's, Burdines-Macy's and Rich's-Macy's. Merger will improve Federated's national marketing initiatives and offer better merchandise assortment at more competitive prices, firm says. Most of May's regional department stores will be converted to the Macy's nameplate. Federated has begun converting its own regional department stores to the Macy's name. Cost synergies from the acquisition are expected to be $175 mil. in 2006 and $450 mil. in 2007, and deal will be accretive to earnings in 2007...
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.